TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04404387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of vitamin C
Description: The intervention is intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).~The other name of the drug: Ascorbic acid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of placebo
Description: Administration of placebo. Patients (in the control arm) will receive dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C. Placebo will be infused over 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute as per the infusion instructions of vitamin C.
Study: NCT05597085

Intervention type: DRUG
Intervention: Inotuzumab Ozogamicin
Description: Inotuzumab Ozogamicin is an Antibody drug conjugate directed against CD 22 positive B Cell ALL
Study: NCT05070975

Intervention type: OTHER
Intervention: Epidemiology
Description: Assessment of the discrepancy of clinical severity of RSV-infections between twin infants.
Study: NCT05762380

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: 2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)
Description: 2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
Study: NCT04327583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPPACTTO
Description: The coordinated experimental pharmaceutical path consists of 7 pharmaceutical interviews or consultations. One initial pharmaceutical consultation with the hospital pharmacist. Five follow-up pharmaceutical interviews with the dispensary pharmacist. One follow-up pharmaceutical consultation with hospital pharmacist.~Each pharmaceutical interview or consultation will result in the drafting of a pharmaceutical report to be sent to the other participating health professionals. At each pharmaceutical consultation or interview, the pharmacists requested perform a clinical pharmaceutical analysis of drug prescriptions; Evaluate the patient's understanding; Detect adherence problems, Identify drug related problems; Alert the oncologist and / or the attending physician.
Study: NCT04688736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The tablet resembles chlorpheniramine but has no therapeutic value.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpheniramine
Description: An antihistamine that reduces the natural chemical histamine in the body.
Study: NCT05354583

Intervention type: DRUG
Intervention: Appropriate treatment
Description: Treatment with at least 3 antibiotics, which the pathogen is susceptible to based on in vitro drug susceptibility test, in the initial phase of the treatment

Intervention type: DRUG
Intervention: Appropriate treatment
Description: Treatment with at least 3 antibiotics, which the pathogen is susceptible to based on in vitro drug susceptibility test, in the initial phase of the treatment
Study: NCT04426877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive the same web-based lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
Study: NCT04647591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Use of a questionnaire focused on diver experience and medical history upon inclusion and another questionnaire in case of ENT Barautrauma over a period of two years to standardize Barotrauma assessment.
Study: NCT01870102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pelubiprofen IR (Pelubiprofen 30mg) TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelubiprofen SR (Pelubiprofen 45 mg) BID

Intervention type: DRUG
Group type: OTHER
Intervention: Pelubiprofen SR (Pelubiprofen 45 mg) BID

Intervention type: DRUG
Group type: OTHER
Intervention: Pelubiprofen SR (Pelubiprofen 45 mg) BID
Study: NCT04712110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-019
Description: TAK-019 intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intramuscular injection
Study: NCT05931237

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry extract capsules
Description: Cranberry extract capsules (Prebiocran(TM))
Study: NCT04512040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: At-Home Yoga
Description: At-home yoga practice over 12 weeks.
Study: NCT06464250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundla care group
Description: A care package consisting of foot examination, correct foot care behaviours, and regular blood glucose monitoring was used.
Study: NCT04459182

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ENDOPAT
Description: digital plethysmography

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: ENDOPAT
Description: digital plethysmography
Study: NCT04866693

Intervention type: OTHER
Intervention: None - this is an exploratory qualitative study to understand patient safety problems in community-based mental healthcare.
Description: Qualitative study

Intervention type: OTHER
Intervention: None - this is an exploratory qualitative study to understand patient safety problems in community-based mental healthcare.
Description: Qualitative study

Intervention type: OTHER
Intervention: None - this is an exploratory qualitative study to understand patient safety problems in community-based mental healthcare.
Description: Qualitative study
Study: NCT04858230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LymphoPilot
Description: LymphoPilot is an investigational medical device composed of an implanted part (pump, drainage catheter and output catheter), implanted in the subcutaneous tissue of the arm or of the leg and draining excess fluids to the supraclavicular or abdominal subcutaneous tissue, where fluids are naturally reabsorbed by the healthy lymphatic and venous system. The implanted part is activated and controlled via a wearable device.~The subcutaneous implantation of the device is performed in loco-regional or general anesthesia, in ambulatorial settings, and the patient is dismissed from the hospital on the same day of the procedure.~Patients will wear the external controller continuously throughout the study, except 30 minutes per day, to allow taking a shower/bath. The implanted device will be removed with a surgical procedure in local anesthesia 8 weeks after device implantation.
Study: NCT06148376

Intervention type: OTHER
Intervention: Personalized treatment
Description: Discontinue prandial insulin treatment
Study: NCT05386901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional positive end-expiratory pressure(PEEP)
Description: Positive end-expiratory pressure is the mechanical ventilator that generates positive pressure during the inspiratory phase to pass gas into the lungs. When the airway opens at the end of expiration, the airway pressure remains above atmospheric pressure to prevent the alveoli from shrinking and collapsing.In this intervention arm It will be set to 5 cmH2O until the end of the operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung dynamic compliance guided positive end-expiratory pressure(PEEP)
Description: Positive end-expiratory pressure is the mechanical ventilator that generates positive pressure during the inspiratory phase to pass gas into the lungs. When the airway opens at the end of expiration, the airway pressure remains above atmospheric pressure to prevent the alveoli from shrinking and collapsing.In this intervention arm It will be set to individual value until the end of the operation.The individualized values are obtained by observing the maximum Lung dynamic compliance during PEEP titration.
Study: NCT05502575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring and personalized stress management
Description: Self-monitoring and personalized stress management education and materials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring and general stress management
Description: Self-monitoring and general stress management education and materials.
Study: NCT06394011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax, azacitidine and HAAG regimen
Description: Venetoclax:100mg, qd, d1;200mg, qd, d2;400 mg, qd, d3\~10, per os; Azacitidine:75mg/m2/d, d1\~7, subcutaneous injection; Homoharringtonine:1mg/d, d4\~10, intravenous infusion; Aclarubicin:10mg/d, d4\~7, intravenous infusion; Cytarabine:10mg/m2,q12h,d4\~10, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;
Study: NCT03141736

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KMC & WHO protocol (0-1 hour)
Description: WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KMC, WHO protocol & bag (0-1 hour)
Description: In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost \[3 cents per bag\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KMC & WHO protocol (1-24 hours)
Description: WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KMC, WHO protocol & bag (1-24 hours)
Description: In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost \[3 cents per bag\]
Study: NCT05654389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of teleconsultation for a patient with a provisional diagnosis of myocardial infarction at the district hospital
Description: Using teleconsultation for a patient with a provisional diagnosis of myocardial infarction during referral from the district hospital to the cardiac centre
Study: NCT06279767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Description: 6-mercaptopurine (6-MP) is a crucial drug in the maintenance phase of acute lymphoblastic leukemia treatment.
Study: NCT06116500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified twin block appliance with expander
Description: These appliances are myofunctional appliance used for treating class II division growing adolescents.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified twin block appliance with expander
Description: These appliances are myofunctional appliance used for treating class II division growing adolescents.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional twin block appliance with expander
Description: These appliances are myofunctional appliances used for treating class II division growing adolescents.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional twin block appliance with expander
Description: These appliances are myofunctional appliances used for treating class II division growing adolescents.
Study: NCT05464888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: +Short AAT
Description: Interaction with therapy dog prior to dental exam, cleaning, and simulated radiographs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: +Long AAT
Description: Interaction with therapy dog throughout dental exam, cleaning, and simulated radiographs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control; NO dog
Description: Color dog picture for 3 minutes prior to dental exam, cleaning, and simulated radiographs.
Study: NCT04677959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FS)
Description: FS administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Albuterol administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Asthma Medication
Description: Current inhaled corticosteroid(ICS)/Long-acting beta agonist(LABA) and any additional controller medication for asthma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Rescue Medication
Description: Current rescue medication
Study: NCT04921735

Intervention type: DRUG
Intervention: Cisatracurium
Description: 0.15 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower

Intervention type: DRUG
Intervention: Cisatracurium
Description: 0.15 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
Study: NCT05590260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV iron infusion
Description: single-dose IV iron infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral iron tablets
Description: 60 mg of elemental iron
Study: NCT05076383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group (Motor relearning program)
Description: Task-specific training based on motor relearning program will be performed for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each training session will consist of five training tasks: (1) bed mobility and sitting up over the side of the bed; (2) balanced sitting; (3) standing up and sitting down; (4) balanced standing; and (5) practice of walking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (Conventional physical therapy program)
Description: The conventional physical therapy program (CPT) exercises will be performed following a standard stroke rehabilitation program for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each CPT rehabilitation session will include the following exercises: (1) passive and active-assisted range of motion; (2) stretching; (3) strengthening exercises; (4) balance exercises; and (5) walking.
Study: NCT05329376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Speaker Echo Dot
Description: Participants will receive the Smart Speaker EchoDot 3rd Gen (Amazon Echo®) device (i.e., Alexa) for home use, installed during a home visit following the study enrollment. In addition to the usual functionality of the system, the device will be programmed using a standard model developed by the research team, applied to each patient. The proposed model involves automatic interactions between the device and the patient, comprising:~1. Medication reminders~2. Glucose test reminders:~3. Educational health tips~4. Weekly educational podcasts~5. Good morning and good night routine

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants will maintain usual care during the study period and will receive a booklet with general advice following enrollment
Study: NCT03957265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tapered abutment connection
Description: Rehabilitation of completely edentulous patients with overdentures prostheses.
Study: NCT05468554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin will be used 3 times a day (3x500mg), starting in the first week with 1x1 tablet (1x500 mg for breakfast), in the second week, 2x1 tablet (500 mg for breakfast and 500 mg for dinner), from the 3rd week 3x1 tablet. (3x500mg with main meals). A gradual escalation of the dose is planned to the point of developing drug intolerance or toxicity that is unacceptable to the patient.
Study: NCT06300112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YOGA
Description: Yoga will be applied to the experimental group for a total of 12 sessions, two sessions per week (90 minutes) for six weeks.
Study: NCT04941209

Intervention type: DEVICE
Intervention: imPulse™ Una infrasound-to-ultrasound e-stethoscope
Description: The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.

Intervention type: DEVICE
Intervention: imPulse™ Una infrasound-to-ultrasound e-stethoscope
Description: The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.

Intervention type: DIAGNOSTIC_TEST
Intervention: (PPA >95%) FDA EUA RT-PCR
Description: Real-time RT-PCR that detects amplified SARS-CoV-2 genome in sputum, nasopharyngeal or oropharyngeal swabs, bronchoalveolar lavage fluid, nasal or nasopharyngeal aspirate, and lower respiratory tract aspirates.

Intervention type: DIAGNOSTIC_TEST
Intervention: (PPA >95%) FDA EUA RT-PCR
Description: Real-time RT-PCR that detects amplified SARS-CoV-2 genome in sputum, nasopharyngeal or oropharyngeal swabs, bronchoalveolar lavage fluid, nasal or nasopharyngeal aspirate, and lower respiratory tract aspirates.

Intervention type: RADIATION
Intervention: HR-CT-scan
Description: High-resolution computer tomography, or CT/CAT, is an X-ray scan that produces images of the chest and is used as a confirmatory test in symptomatic patients that have a negative PCR test.
Study: NCT05060367

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomal multivitamin/mineral
Description: Two-capsule dose of liposomal multivitamin/mineral that is nutrient-matched to the standard multivitamin/mineral.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard multivitamin/mineral
Description: Two-capsule dose of standard multivitamin/mineral that is nutrient-matched to the liposomal multivitamin/mineral.
Study: NCT04911452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calmer
Description: Once randomized, infants in the Calmer group will receive treatment for a minimum cumulative total of 3 hours/day during periods when the infant may be too ill to be held or when parents do not wish to hold their infant or are not present. Calmer does not replicate a parent's contact and so the minimum exposure has been tripled. No upper limit of Calmer use will be set. Each day, the research and/or bedside nurse will record the heart and respiratory rates for a two-minute period. The one-minute average will be used to program Calmer for each infant that day to better simulate day-to-day changes in infant-parent contact. The Neonatal Intensive Care Unit (NICU) research nurse will also train the parents/caregivers to self-measure their resting heart and breathing rates so that if they are away from the NICU for more than one day, these values can be sent to the research/ bedside nurse by phone.
Study: NCT06267755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave therapy
Description: the patients will receive Extracorporeal Shockwave therapy sessions by 600 impulses with 1.6 bar pressure at a frequency of 8 Hz on site of the upper trapezius

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy
Description: the patients will receive Traditional physical therapy in the form of Integrated neuro-muscular inhibition technique + posture correction and scapular stabilization exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: the patients will receive Traditional physical therapy in the form of Integrated neuro-muscular inhibition technique + posture correction and scapular stabilization exercises.
Study: NCT05738642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 factor Prothrombin Complex Concentrates
Description: Cluster 4 f - PCC by intravenous infusion (boya 4 f - PCC, a bottle of 400 IU) : 25 IU/kg dose infusion time: as soon as possible after admission infusion, at the latest within 2 hours after admission to infusion infusion method: Sodium chloride injection 5% glucose injection was diluted into 50 ml per bottle, and then intravenous infusion was carried out with a blood transfusion device with a mesh device. The infusion was finished in 60-120 minutes
Study: NCT05468554

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioactive iodine (I-131)
Description: Patients qualified to receive 131I treatment

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radioactive iodine (I-131)
Description: Patients qualified to receive 131I treatment
Study: NCT05293834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Aggression Prevention Training (VRAPT)
Description: VRAPT consists of sixteen 45- to 60-minute sessions that take place once or twice per week (total duration of the intervention = 8 to 16 weeks). Session time and intensity will be adapted to the individual participant and the sessions will be delivered by specially trained VRAPT therapists in individual settings. The immersive and interactive three-dimensional virtual environment will be presented via headphones and head-mounted displays, using software developed by CleVR. In the virtual environment, participants will interact with virtual characters that are controlled by the psychotherapist and practice new skills . The therapy program is targeted at factors and processes related to aggression and the underlying theoretical framework is based on cognitive behavioural therapy and the General Aggression Model (GAM).~The VRAPT consists of 4 phases:~1. Introduction (Session 1)~2. Inventory phase (Sessions 2-6)~3. Skills-training (Sessions 6-15)~4. Evaluation (Session 16)